Android app Apple app link

Eton acquires US rights to neonatal diabetes treatment from AMMTeK

By Yahoo! Finance   |   1 month ago
Eton acquires US rights to neonatal diabetes treatment from AMMTeK

Eton Pharmaceuticals has obtained the US rights to Amglidia, a treatment for neonatal diabetes mellitus, from French biotechnology company AMMTeK.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.